# Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

Source: https://onco.cc/trials/nct07491445/  
OnCo record `nct07491445` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daraxonrasib, Gemcitabine, Paclitaxel / nab-paclitaxel in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma is a phase 3 interventional study registered as NCT07491445 by Revolution Medicines, Inc., with 900 participants planned, started 2026-03-09 and due to reach its primary completion in 2028-06. Interventions recorded: daraxonrasib, gemcitabine, nab-paclitaxel. Conditions listed: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Also known as: RASolute 303
- Tags: ctgov-ingest
- Registry id: NCT07491445
- Phase: 3
- Setting: RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 900

## Notes

- RASolute 303 (registry, 24 September 2026): phase 3, three arms, daraxonrasib alone or with gemcitabine and nab-paclitaxel against gemcitabine and nab-paclitaxel as first-line treatment for metastatic pancreatic adenocarcinoma; 900 participants (estimated), recruiting, started 9 March 2026, primary completion June 2028; progression-free and overall survival primary endpoints. UK sites (6): Torbay Hospital, Queen Elizabeth Hospital Birmingham, Addenbrooke's Cambridge, Barts (London), Royal Marsden (London), the Christie (Manchester).

## Sources

- ClinicalTrials.gov NCT07491445: https://clinicaltrials.gov/study/NCT07491445

## Connected records

- cancers: [BRCA or PALB2-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/brca-palb2-pdac/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)
- trials: [MPACT](https://onco.cc/trials/mpact/), [RASolute 302](https://onco.cc/trials/rasolute-302/)
- roadmaps: [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- ideas: [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/), [Off-the-shelf KRAS vaccines after pancreatic cancer surgery](https://onco.cc/ideas/idea-shared-kras-vaccine-adjuvant/), [RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression](https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/)

---
JSON: https://onco.cc/api/v1/entities/nct07491445.json